Evidence map›Paper›PMID 37389430›Full record

ArticlemSphere2023

Targeted gene deletions in the dimorphic fungal pathogen

Chad A Rappleye

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Tools for genetic manipulation of the endemic fungal pathogen,bioRxiv : the preprint server for biology · 2025
    Article
  4. Advancing sustainable practices withAIMS microbiology · 2025
    Review
  5. Article
  6. Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  7. mBio · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Chad A RappleyeDepartment of Microbiology, Ohio State University , Columbus, Ohio, USA.ORCID 0000-0001-7880-5958
The Ohio State University · US

Funding

Intracellular Proliferation of the fungal pathogen Histoplasma capsulatumR01AI148561 · NIAID · OHIO STATE UNIVERSITY · PI Chad A Rappleye · 2020 to 2026
$2.5M
NIAID NIH HHS R01 AI148561
6 · The paper itself

Abstract

The rapid development of CRISPR/CRISPR-associated (Cas) systems has revolutionized the ability to produce genetic mutations in a desired locus, particularly in organisms with low rates of homologous recombination.

Indexed as

CRISPR-Cas SystemsGene EditingGene DeletionHistoplasmaPlasmidsCRISPRgenome editingHistoplasma

Identifiers

PMID37389430
PMCPMC10449496
OpenAlexW4382631147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.